tiprankstipranks
Kyverna shares remain ‘significantly under-valued,’ says JPMorgan
PremiumThe FlyKyverna shares remain ‘significantly under-valued,’ says JPMorgan
2M ago
Premium
Company Announcements
Kyverna CMO Resignation Highlights Leadership Transition Impact
2M ago
Kyverna Therapeutics price target lowered to $6 from $7 at H.C. Wainwright
Premium
The Fly
Kyverna Therapeutics price target lowered to $6 from $7 at H.C. Wainwright
2M ago
Kyverna Therapeutics reports Q3 EPS (80c), consensus (79c)
PremiumThe FlyKyverna Therapeutics reports Q3 EPS (80c), consensus (79c)
3M ago
Premium
Company Announcements
Kyverna Therapeutics Strengthens Board with New Appointment
3M ago
Kyverna Therapeutics initiated with a Buy at UBS
Premium
The Fly
Kyverna Therapeutics initiated with a Buy at UBS
4M ago
Kyverna Therapeutics names Warner Biddle as CEO, succeeding Peter Maag
PremiumThe FlyKyverna Therapeutics names Warner Biddle as CEO, succeeding Peter Maag
5M ago
Kyverna Therapeutics treatment of stiff person syndrome gets orphan designation
Premium
The Fly
Kyverna Therapeutics treatment of stiff person syndrome gets orphan designation
5M ago
Kyverna Therapeutics price target lowered to $7 from $8 at H.C. Wainwright
Premium
The Fly
Kyverna Therapeutics price target lowered to $7 from $8 at H.C. Wainwright
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100